Acepodia, Inc. (TPEX:6976)
Taiwan · Delayed Price · Currency is TWD 12.30
+0.20 (1.65%)
Apr 17, 2026, 1:38 PM CST
Acepodia Revenue
In the year 2025, Acepodia had annual revenue of 185.00K TWD, down -56.67%.
Revenue
185.00K
Revenue Growth
-56.67%
P/S Ratio
39,181.81
Revenue / Employee
n/a
Employees
n/a
Market Cap
7.25B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 185.00K | -242.00K | -56.67% |
| Dec 31, 2024 | 427.00K | -16.17M | -97.43% |
| Dec 31, 2023 | 16.59M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sinphar Pharmaceutical | 3.37B |
| Panion & Bf Biotech | 2.06B |
| Adimmune | 1.40B |
| Savior Lifetec | 1.20B |
| PharmaEngine | 911.42M |
| Mycenax Biotech | 740.24M |
| TaiGen Biopharmaceuticals Holdings | 259.47M |
| Gongwin Biopharm Holdings | 36.45M |